Arianne Tardif,G A Whitmore,Katherine L Vandemheen,Celine Bergeron,Louis-Philippe Boulet,Andréanne Côté,R Andrew McIvor,Erika Penz,Stephen K Field,Catherine Lemière,Irvin Mayers,Mohit Bhutani,Tanweer Azher,M Diane Lougheed,Samir Gupta,Nicole Ezer,Christopher J Licskai,Paul Hernandez,Martha Ainslie,Gonzalo G Alvarez,Sunita Mulpuru,Shawn D Aaron
{"title":"Patient Factors and Clinical Efficacy of Early Identification and Treatment of COPD and Asthma.","authors":"Arianne Tardif,G A Whitmore,Katherine L Vandemheen,Celine Bergeron,Louis-Philippe Boulet,Andréanne Côté,R Andrew McIvor,Erika Penz,Stephen K Field,Catherine Lemière,Irvin Mayers,Mohit Bhutani,Tanweer Azher,M Diane Lougheed,Samir Gupta,Nicole Ezer,Christopher J Licskai,Paul Hernandez,Martha Ainslie,Gonzalo G Alvarez,Sunita Mulpuru,Shawn D Aaron","doi":"10.1164/rccm.202505-1260oc","DOIUrl":null,"url":null,"abstract":"RATIONALE\r\nThe Undiagnosed COPD and Asthma Population trial showed that early diagnosis and treatment of asthma and COPD by pulmonologists improved healthcare utilization, respiratory symptoms, and quality of life.\r\n\r\nOBJECTIVES\r\nTo determine if the benefits of early diagnosis and treatment were greater in individuals with more advanced disease, or in individuals with asthma as opposed to COPD. We also assessed whether pulmonologist-directed care benefited asthma and COPD subgroups equally.\r\n\r\nMETHODS\r\nCase finding was used to identify undiagnosed adults with chronic respiratory symptoms in the community. Five hundred and eight newly diagnosed participants with COPD or asthma were randomized to a pulmonologist-care intervention or usual care. Low and high disease-burden categories for St. Georges Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) were defined using a median-split of baseline scores, and MCID thresholds were used to define significant responses. Benefits of pulmonologist care were assessed by evaluating treatment effects within subgroups and by assessing treatment-by-subgroup interactions.\r\n\r\nMEASUREMENTS AND MAIN RESULTS\r\nPatients with higher disease burden at diagnosis were more likely to benefit from early diagnosis and treatment compared to those with lower disease-burden. 71% of those with high disease-burden improved their CAT by ≥ 2 points over 12 months compared to 47% with low disease burden; OR 2.78, 95% CI: 1.90 to 4.07, p<0.001. Similar results were seen for SGRQ and FEV1 improvements. In contrast, responses to early diagnosis and treatment were similar for those with asthma vs COPD. Individuals with asthma randomized to pulmonologist-directed care showed greater one-year improvements in CAT, SGRQ, SF36 and FEV1 compared to individuals randomized to primary care. However, individuals with COPD experienced similar improvements regardless of whether their treatment was managed by a pulmonologist or primary care provider. Treatment-by-disease interaction terms were not statistically significant.\r\n\r\nCONCLUSIONS\r\nPatients with greater disease burden who exhibited more advanced and symptomatic asthma and COPD at the time of diagnosis, benefited more from earlier diagnosis and treatment. Patients with asthma tended to derive greater benefit from pulmonologist-directed care than patients with COPD.","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":"4 1","pages":""},"PeriodicalIF":19.4000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of respiratory and critical care medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1164/rccm.202505-1260oc","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
RATIONALE
The Undiagnosed COPD and Asthma Population trial showed that early diagnosis and treatment of asthma and COPD by pulmonologists improved healthcare utilization, respiratory symptoms, and quality of life.
OBJECTIVES
To determine if the benefits of early diagnosis and treatment were greater in individuals with more advanced disease, or in individuals with asthma as opposed to COPD. We also assessed whether pulmonologist-directed care benefited asthma and COPD subgroups equally.
METHODS
Case finding was used to identify undiagnosed adults with chronic respiratory symptoms in the community. Five hundred and eight newly diagnosed participants with COPD or asthma were randomized to a pulmonologist-care intervention or usual care. Low and high disease-burden categories for St. Georges Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) were defined using a median-split of baseline scores, and MCID thresholds were used to define significant responses. Benefits of pulmonologist care were assessed by evaluating treatment effects within subgroups and by assessing treatment-by-subgroup interactions.
MEASUREMENTS AND MAIN RESULTS
Patients with higher disease burden at diagnosis were more likely to benefit from early diagnosis and treatment compared to those with lower disease-burden. 71% of those with high disease-burden improved their CAT by ≥ 2 points over 12 months compared to 47% with low disease burden; OR 2.78, 95% CI: 1.90 to 4.07, p<0.001. Similar results were seen for SGRQ and FEV1 improvements. In contrast, responses to early diagnosis and treatment were similar for those with asthma vs COPD. Individuals with asthma randomized to pulmonologist-directed care showed greater one-year improvements in CAT, SGRQ, SF36 and FEV1 compared to individuals randomized to primary care. However, individuals with COPD experienced similar improvements regardless of whether their treatment was managed by a pulmonologist or primary care provider. Treatment-by-disease interaction terms were not statistically significant.
CONCLUSIONS
Patients with greater disease burden who exhibited more advanced and symptomatic asthma and COPD at the time of diagnosis, benefited more from earlier diagnosis and treatment. Patients with asthma tended to derive greater benefit from pulmonologist-directed care than patients with COPD.
期刊介绍:
The American Journal of Respiratory and Critical Care Medicine focuses on human biology and disease, as well as animal studies that contribute to the understanding of pathophysiology and treatment of diseases that affect the respiratory system and critically ill patients. Papers that are solely or predominantly based in cell and molecular biology are published in the companion journal, the American Journal of Respiratory Cell and Molecular Biology. The Journal also seeks to publish clinical trials and outstanding review articles on areas of interest in several forms. The State-of-the-Art review is a treatise usually covering a broad field that brings bench research to the bedside. Shorter reviews are published as Critical Care Perspectives or Pulmonary Perspectives. These are generally focused on a more limited area and advance a concerted opinion about care for a specific process. Concise Clinical Reviews provide an evidence-based synthesis of the literature pertaining to topics of fundamental importance to the practice of pulmonary, critical care, and sleep medicine. Images providing advances or unusual contributions to the field are published as Images in Pulmonary, Critical Care, Sleep Medicine and the Sciences.
A recent trend and future direction of the Journal has been to include debates of a topical nature on issues of importance in pulmonary and critical care medicine and to the membership of the American Thoracic Society. Other recent changes have included encompassing works from the field of critical care medicine and the extension of the editorial governing of journal policy to colleagues outside of the United States of America. The focus and direction of the Journal is to establish an international forum for state-of-the-art respiratory and critical care medicine.